The investigational new drug applications (INDs) are for Sym022 and Sym023, which are being investigated for potential use as treatments for locally advanced/unresectable or metastatic solid tumours or lymphomas that are refractory to available therapy or for which no standard therapy is available.
Selexis revealed that Symphogen will utilise its Selexis Genetic Elements (SGE) technology to advance the two potential drug candidates.
This comes after Symphogen had previously, in 2016, used the SGE technology to advance Sym015, a novel antibody mixture containing two humanised monoclonal antibodies (mAbs), through to clinical development, according to the companies.
“Selexis and Symphogen have had a great working relationship over the past several years and we are proud to expand our partnership through these two additional programs based on the success they have had using our SUREtechnology platform,” said Marco Bocci, Selexis vice president, licensing and business development.
Symphogen has been working with Selexis’ SUREtechnology platform from 2014, while earlier this year Compugen also announced it would work with the technology to generate research cell banks and develop its immuno-oncology products.
With the number of its partnerships increasing, Selexis announced that it would invest to improve the delivery times of its research cell banks, in April 2018.